中關村(000931.SZ):擬與優迅醫學就醫藥大健康等領域展開戰略合作
格隆匯5月24日丨中關村(000931.SZ)公佈,2022年5月23日,北京中關村科技發展(控股)股份有限公司(“甲方”)與北京優迅醫學檢驗實驗室有限公司(簡稱:優迅醫學,“乙方”)在北京簽署《合作框架協議》。
協議主要內容:1、利用甲方在運營和渠道方面的優勢及乙方在新冠檢測領域的專業優勢,於乙方取得的新型冠狀病毒(2019-nCoV)核酸檢測點內,開展新冠病毒核酸篩查合作,取得的相關收益,雙方協商分成;2、利用甲方在生物醫藥領域的研發生產能力及中醫醫院、養老院的專業背景、醫藥銷售渠道及網絡佈局和乙方現有產品在基因檢測方面開展多層次合作;3、利用甲方上市公司背景及在醫療、養老方面的優勢與乙方的專業檢測能力和社會資源,開展在資本市場的合作。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.